| With years of research already behind it, (SILO) is no longer just a concept-stage biotech. The timeline to clinical trials is now clear.
Following FDA guidance and successful pre-IND developments, SPC-15 may soon transition from lab studies to real-world human use cases.
At the same time, the company’s expansion into Alzheimer’s disease and MS research through candidates SPC-14 and SPU-16demonstrates a broader ambition to make measurable impacts across multiple neurological frontiers—many of which have seen little innovation for decades.
This next phase, if executed well, could be where everything changes.
As momentum builds, technicals shift, and the company checks off meaningful milestones—there’s a growing sense that (SILO) may no longer stay under the radar.
The chart has history.
The pipeline has depth.
And the timing? That’s what makes this one worth watching.
Here’s what we’re seeing right now—fact by fact—that has our full focus going into the morning.
5 Reasons Why We Have All Eyes On (SILO) This Morning…
1. Recent Market Recognition: (SILO) moved approximately 51% in one week—from $0.74 on May 5 to $1.12 early yesterday, May 13th—while trending above both its 5- and 20-day moving averages.
2. Limited Float: With fewer than 5M shares listed, (SILO) sits in a held range that has historically amplified swing potential when momentum builds.
3. Breakout History: Back in July 2024, (SILO) moved from $0.841 to $4.50 in under two weeks, marking an approximate 435% move that still draws attention when looking at the chart.
4. Flying Under The Radar: Despite clinical progress, new filings, and licensing from Columbia University, (SILO) continues to hold a market cap below $5M as of today.
5. Trial Timeline Advancing: (SILO)’s lead program SPC-15 is in final IND-enabling studies, following FDA alignment for a streamlined clinical path using the 505(b)(2) route.
Each of these factors adds weight on its own—but together, they paint a picture that’s hard to ignore.
Momentum appears to be building in multiple areas at once—technical, structural, and scientific.
And if the name stays on track, this could be one of the more talked-about early-stage biotech setups heading into the summer.
Pull Up (SILO) This Morning While It’s Still Early…
As clinical progress accelerates and technical signals begin to align, Silo Pharma (NASDAQ: SILO) continues to stand out for reasons both structural and scientific.
From its under-the-radar valuation to its tightening float and regulatory momentum, this is a name that has quietly built the foundation for broader recognition.
We have (SILO) at the top of our screens right now.
Pull up (SILO) while it’s still early.
(SILO) reached $2.33 in the early session—marking an approximate 111% overnight move from yesterday’s $1.10 close.
When there’s a limited float, in (SILO)’s case, fewer than 5M, there’s the potential for big swings like this when demand shifts.
Keep an eye out for my next update—it could be coming at any moment. |
